{"trials":[{"id":3481,"nct_id":"NCT04959253","title":"A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study","sponsor":"King's College London","registry_url":"https://clinicaltrials.gov/study/NCT04959253","tracker_url":"publication.php?id=3481","status":"COMPLETED","status_label":"Completed","status_verified_date":"2021-06","last_update_date":"2026-08-28","start_date":"2021-06-21","primary_completion_date":"2024-12-18","completion_date":"2024-12-18","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin assisted therapy","type":"COMBINATION_PRODUCT"},{"name":"Placebo assisted therapy","type":"COMBINATION_PRODUCT"}],"substances":["psilocybin"],"sites":[{"key":"2af82304b750e5e49e9f89c722d44575fe6978541c1a1e315e0c160897006053","facility":"Clinical Research Facility, King's College Hospital","city":"London","region":"London","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3630,"nct_id":"NCT05723276","title":"Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)","sponsor":"King's College London","registry_url":"https://clinicaltrials.gov/study/NCT05723276","tracker_url":"publication.php?id=3630","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-07","last_update_date":"2026-07-23","start_date":"2024-02-14","primary_completion_date":"2026-04-14","completion_date":"2026-07-07","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Functional Neurological Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"8cd5c53de095e8abbdf7d2a81b2bc34a9a6968c44ae8f4eb45dc82ef2cf7b17c","facility":"South London and Maudsley NHS Foundation Trust","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3541,"nct_id":"NCT07050368","title":"A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers","sponsor":"MycoMedica Life Sciences PBC","registry_url":"https://clinicaltrials.gov/study/NCT07050368","tracker_url":"publication.php?id=3541","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-02","last_update_date":"2026-02-13","start_date":"2025-07-28","primary_completion_date":"2026-01-13","completion_date":"2026-01-13","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Healthy Volunteer"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"acb92468b8bdb8e495997bdcc5a1aab1cb194abab89bbb8f698d935f8a4f86a9","facility":"Hammersmith Medicines Research (HMR)","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3625,"nct_id":"NCT06798636","title":"Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT06798636","tracker_url":"publication.php?id=3625","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-12-05","start_date":"2025-10-01","primary_completion_date":"2026-08-31","completion_date":"2026-10-31","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"TRIPLE"},"conditions":["Self Harm"],"interventions":[{"name":"Psilocybin 5 mg with cognitive behavioural therapy intervention","type":"DRUG"},{"name":"Placebo with cognitive behavioural therapy intervention","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bd9ef7ba5708708e271ac4223cd8f759659fe972f273d761152a6c0134e8622e","facility":"Imperial College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3698,"nct_id":"NCT06815653","title":"Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.","sponsor":"University College, London","registry_url":"https://clinicaltrials.gov/study/NCT06815653","tracker_url":"publication.php?id=3698","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-02","last_update_date":"2025-11-26","start_date":"2025-03-01","primary_completion_date":"2026-03","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"SINGLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin 25mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6ca657d87e4528cc481a8c1baf8515a664bf591f795d28d79266623762f21568","facility":"University College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3699,"nct_id":"NCT07164755","title":"Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.","sponsor":"King's College London","registry_url":"https://clinicaltrials.gov/study/NCT07164755","tracker_url":"publication.php?id=3699","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-09","last_update_date":"2025-09-10","start_date":"2021-06-21","primary_completion_date":"2026-09","completion_date":"2026-09","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":46,"type":"ACTUAL"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["Depression - Major Depressive Disorder"],"interventions":[],"substances":["psilocybin"],"sites":[{"key":"84d3b2e5a3a8521c2be63f3b94f0d00d44e1ecaff45bb8e80b74fbc4dd66bb3c","facility":"King's College London Institute of Psychiatry, Psychology and Neuroscience","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3424,"nct_id":"NCT05651126","title":"Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD)","sponsor":"King's College London","registry_url":"https://clinicaltrials.gov/study/NCT05651126","tracker_url":"publication.php?id=3424","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-03","last_update_date":"2025-07-28","start_date":"2022-12-12","primary_completion_date":"2024-08-23","completion_date":"2024-08-23","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":67,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Autism Spectrum Disorder"],"interventions":[{"name":"Psilocybin 5 mg","type":"DRUG"},{"name":"Psilocybin 2 mg","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"a2a4ed472d0c860a706d8a130661a9baa3742799c37bd96f2f64a1cdd0866b66","facility":"King's College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3482,"nct_id":"NCT05312151","title":"The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT05312151","tracker_url":"publication.php?id=3482","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-05","last_update_date":"2025-06-13","start_date":"2022-06-10","primary_completion_date":"2024-02-12","completion_date":"2024-02-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":22,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post Traumatic Stress Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"52db1aeead88bb42011a4764f5c07cbf6c76496768465bd5c4fcd8e25775a003","facility":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"6332cc00e1ef6b028ce5b2931bc428fb44a6e2eca82b5135ec346b7ceedf62ae","facility":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"190dd76ab65ad7b28570cf2992585e62e7281887f8f4acc4cc7ee1b0ebcb7c7e","facility":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United States","United Kingdom"]},{"id":3689,"nct_id":"NCT05481736","title":"Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT05481736","tracker_url":"publication.php?id=3689","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-12","last_update_date":"2024-12-04","start_date":"2022-10-12","primary_completion_date":"2024-11-18","completion_date":"2024-11-18","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":32,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b62c29cd779fd43501f426fef3293a64089108a0e7e17ae13b4044a87d256c81","facility":"Altman Clinical and Translational Research Institute","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"bc376e1e0a696ea23f74184c3639e3209c4cf2754b05d49dcebccf226428bc05","facility":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"44dff036ba0c252b89f384cafd7b6afe7f6dbbde33d112b5813eb8a58984f3ba","facility":"Dell Medical School","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"1936d05fa8ae325b9934cffa0a0c3f08afa8e902d6fe3597cf7ffaec91b70308","facility":"Tallaght University Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"190dd76ab65ad7b28570cf2992585e62e7281887f8f4acc4cc7ee1b0ebcb7c7e","facility":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United States","Ireland","United Kingdom"]},{"id":3669,"nct_id":"NCT06258031","title":"PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT06258031","tracker_url":"publication.php?id=3669","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-11","last_update_date":"2024-11-06","start_date":"2022-10-28","primary_completion_date":"2024-06-28","completion_date":"2024-07-24","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":19,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin (COMP360)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"cd53ff909631c02493009d6fa3e945541560209fce31bf8b65855864408557b7","facility":"CIPPRes Clinic","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3644,"nct_id":"NCT03429075","title":"Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT03429075","tracker_url":"publication.php?id=3644","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-08","last_update_date":"2024-10-24","start_date":"2019-01-07","primary_completion_date":"2020-04-17","completion_date":"2020-10-17","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":59,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Depressive Disorder, Major"],"interventions":[{"name":"Psilocybin + Placebo","type":"DRUG"},{"name":"Psilocybin + Escitalopram","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"92f7e0cc003e9611ea48c068566e59f517929115533a6bed42bf34a1e382a8a8","facility":"Imperial College Hammersmith campus","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3462,"nct_id":"NCT04505189","title":"Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT04505189","tracker_url":"publication.php?id=3462","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-06","last_update_date":"2024-06-17","start_date":"2021-05-28","primary_completion_date":"2023-12-11","completion_date":"2024-06-12","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":21,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"92f7e0cc003e9611ea48c068566e59f517929115533a6bed42bf34a1e382a8a8","facility":"Imperial College Hammersmith campus","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3499,"nct_id":"NCT05548075","title":"Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT05548075","tracker_url":"publication.php?id=3499","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2024-01","last_update_date":"2024-01-19","start_date":"2022-08-15","primary_completion_date":"2024-01-10","completion_date":"2024-07-30","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["Fibromyalgia"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Therapeutic support","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"bd9ef7ba5708708e271ac4223cd8f759659fe972f273d761152a6c0134e8622e","facility":"Imperial College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3475,"nct_id":"NCT05876481","title":"Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans","sponsor":"Combat Stress","registry_url":"https://clinicaltrials.gov/study/NCT05876481","tracker_url":"publication.php?id=3475","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2023-05","last_update_date":"2023-05-25","start_date":"2023-06","primary_completion_date":"2025-07","completion_date":"2025-08","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":8,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9b630a2a90cc4073ef88d0ddbb37bf0acd68f69db35ab18518826ea459738714","facility":"Combat Stress","city":"Leatherhead","region":"Surrey","country":"United Kingdom","lat":51.296520000000001,"lon":-0.33379999999999999}],"countries":["United Kingdom"]},{"id":3563,"nct_id":"NCT03775200","title":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT03775200","tracker_url":"publication.php?id=3563","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-04","last_update_date":"2023-04-24","start_date":"2019-03-01","primary_completion_date":"2021-07-30","completion_date":"2021-09-27","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":233,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"b902b2ed0312cb2a3cc5ba1cbae37f314afc33004604dfd9c9cef9895f4cf659","facility":"Altman Clinical and Translational Research Institute, University of California","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"98e89c02051d49d5ecbaeeb42b54b85d2011fdba360a21f7bb381022221609db","facility":"Stanford Department of Psychiatry","city":"Stanford","region":"California","country":"United States","lat":37.424109999999999,"lon":-122.16607999999999},{"key":"4a761e46fb0059d7f502f97e7ff683ed2ef7e77e5bb9c131a2f074aa39eba6a4","facility":"Mood and Anxiety Disorders Program Emory University School of Medicine","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"f364e291f7f50ffe0211133728e04e54d4b08d8bbf7f1e2e84acca880af73791","facility":"Ray Worthy Psychiatry LLC","city":"New Orleans","region":"Louisiana","country":"United States","lat":29.954650000000001,"lon":-90.075069999999997},{"key":"bc376e1e0a696ea23f74184c3639e3209c4cf2754b05d49dcebccf226428bc05","facility":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"9f6dd6c250948ab5fb811774c2613bdc33238e29b80a54c99b31bd3b33684089","facility":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"bc6f21f5dce4d260a52c1cf80e4684418e2cef5172a8a249513f0bd649090cc4","facility":"UT Center of Excellence on Mood Disorders, University of Texas Health Science Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"4518bb99925a2afc34b082750c6bbd85e5a2401e5aedd715ecf330439d7becd3","facility":"Canadian Rapid Treatment Centre of Excellence","city":"Mississauga","region":"Ontario","country":"Canada","lat":43.578899999999997,"lon":-79.658299999999997},{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"fcbe4ef7ab96b23d49f2236d5eef4a63ae4ba8b1ef6fda33e2d4ecdfcd59a37c","facility":"National Institute of Mental Health Czech Republic","city":"Klecany","region":"","country":"Czechia","lat":50.175989999999999,"lon":14.411479999999999},{"key":"4325121d3f92a59587a95d740aec742f926476ae029c126cfb5dca75235c060c","facility":"Enhed for Psykiatrisk Forskning, Psykiatrien i Aalborg","city":"Aalborg","region":"","country":"Denmark","lat":57.048000000000002,"lon":9.9186999999999994},{"key":"acb48d7ccc1915a74261eb4d19980566f9e91227b002d29827c3b573468fca20","facility":"Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin","city":"Berlin","region":"","country":"Germany","lat":52.524369999999998,"lon":13.41053},{"key":"1936d05fa8ae325b9934cffa0a0c3f08afa8e902d6fe3597cf7ffaec91b70308","facility":"Tallaght University Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"4676f983baba50649c69d87e10227647f558552da403e1c02eb74db43f5954ef","facility":"Groningen University Medical Centre","city":"Groningen","region":"","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"e3f0197997fa9570956493b45ec7d746c6d8470a0084194ccfaca38d381335d5","facility":"Leiden University Medical Centre","city":"Leiden","region":"","country":"Netherlands","lat":52.158329999999999,"lon":4.4930599999999998},{"key":"8739aa2791a55723dbde929d6b1781e8da3c89797ac9f3c5cdcebc53f0be213d","facility":"Utrecht University Medical Centre","city":"Utrecht","region":"","country":"Netherlands","lat":52.090829999999997,"lon":5.1222200000000004},{"key":"0825127fed75b48491c482e72ff85f37b6d6a30ff270fa31a00aa738dfdab8b5","facility":"Unidade de Neuropsiquiatria, Centro Clinico Champalimaud","city":"Lisbon","region":"","country":"Portugal","lat":38.725090000000002,"lon":-9.1498000000000008},{"key":"8f7b027dc17f2a210264a5079ecaf11ec7851ea8acc52e06427fe3f08b1d2d69","facility":"Hospital de Dia Numancia","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"591cc23da3dbb467891a35aca8c18e00a3a00b36e679e2bc3a5c63f9cf912dff","facility":"Institute Hospital del Mar of Medical Research (IMIM)","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"4cb30a0cc2db1ef7bb013544a9f7756b74181b28b02d444b55518e6a7c5edd95","facility":"Clinical Research and Imaging Centre","city":"Bristol","region":"Avon","country":"United Kingdom","lat":51.45523,"lon":-2.5966499999999999},{"key":"ca5a318b9a8ab497d31d6e617a67f5536afaff42907d21d3392ac8c92cf5b910","facility":"Wolfson Research Centre, Campus for Ageing and Vitality","city":"Newcastle upon Tyne","region":"Tyne and Wear","country":"United Kingdom","lat":54.973280000000003,"lon":-1.6139600000000001},{"key":"2af6f49013d0328846d4ce8ee776c303f013ff687e95fd27fa857af0c681008b","facility":"St. Pancras Clinical Research","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"190dd76ab65ad7b28570cf2992585e62e7281887f8f4acc4cc7ee1b0ebcb7c7e","facility":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"49c938f65ac4e8234198d3d31829a1e4505a68760ed1739762448f71dbb85a8c","facility":"Greater Manchester Mental Health Foundation Trust","city":"Manchester","region":"","country":"United Kingdom","lat":53.48095,"lon":-2.2374299999999998}],"countries":["United States","Canada","Czechia","Denmark","Germany","Ireland","Netherlands","Portugal","Spain","United Kingdom"]},{"id":3685,"nct_id":"NCT04905121","title":"An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)","sponsor":"Beckley Psytech Limited","registry_url":"https://clinicaltrials.gov/study/NCT04905121","tracker_url":"publication.php?id=3685","status":"TERMINATED","status_label":"Terminated","status_verified_date":"2022-10","last_update_date":"2022-10-12","start_date":"2021-08-11","primary_completion_date":"2022-04-22","completion_date":"2022-04-22","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":4,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Short Lasting Unilateral Neuralgiform Headache Attacks"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"a2a4ed472d0c860a706d8a130661a9baa3742799c37bd96f2f64a1cdd0866b66","facility":"King's College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3477,"nct_id":"NCT04519957","title":"Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT04519957","tracker_url":"publication.php?id=3477","status":"COMPLETED","status_label":"Completed","status_verified_date":"2022-09","last_update_date":"2022-09-22","start_date":"2020-07-20","primary_completion_date":"2022-08-11","completion_date":"2022-08-11","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":66,"type":"ACTUAL"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["Treatment Resistant Depression"],"interventions":[],"substances":["psilocybin"],"sites":[{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"b902b2ed0312cb2a3cc5ba1cbae37f314afc33004604dfd9c9cef9895f4cf659","facility":"Altman Clinical and Translational Research Institute, University of California","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"4a761e46fb0059d7f502f97e7ff683ed2ef7e77e5bb9c131a2f074aa39eba6a4","facility":"Mood and Anxiety Disorders Program Emory University School of Medicine","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"bc6f21f5dce4d260a52c1cf80e4684418e2cef5172a8a249513f0bd649090cc4","facility":"UT Center of Excellence on Mood Disorders, University of Texas Health Science Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"fcbe4ef7ab96b23d49f2236d5eef4a63ae4ba8b1ef6fda33e2d4ecdfcd59a37c","facility":"National Institute of Mental Health Czech Republic","city":"Klecany","region":"","country":"Czechia","lat":50.175989999999999,"lon":14.411479999999999},{"key":"27288850d009a8b31ead8ba5cf86982457592df2fa39c3adaf10d04517cf8a5c","facility":"Sheaf House, Tallaght Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"4676f983baba50649c69d87e10227647f558552da403e1c02eb74db43f5954ef","facility":"Groningen University Medical Centre","city":"Groningen","region":"","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"190dd76ab65ad7b28570cf2992585e62e7281887f8f4acc4cc7ee1b0ebcb7c7e","facility":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United States","Czechia","Ireland","Netherlands","United Kingdom"]},{"id":3583,"nct_id":"NCT03661125","title":"A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.","sponsor":"King's College London","registry_url":"https://clinicaltrials.gov/study/NCT03661125","tracker_url":"publication.php?id=3583","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2018-08","last_update_date":"2019-08-13","start_date":"2019-04-11","primary_completion_date":"2021-09-01","completion_date":"2021-09-01","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Parkinson Disease Psychosis"],"interventions":[{"name":"Saracatinib","type":"DRUG"},{"name":"Placebo Oral Tablet","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"07a8178170a30179f640b9c70731e1d415c7038aab9705b99f55e89c1cc1fb21","facility":"Mitul Mehta","city":"London","region":"Camberwell","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2019":3,"2020":1,"2021":4,"2022":5,"2023":1,"2024":1,"2025":3},"statuses":{"Completed":11,"Unknown status":3,"Recruiting":2,"Active, not recruiting":1,"Terminated":1},"conditions":{"Treatment Resistant Depression":3,"Anorexia Nervosa":2,"Functional Neurological Disorder":1,"Healthy Volunteer":1,"Self Harm":1,"Healthy":1,"Depression - Major Depressive Disorder":1,"Autism Spectrum Disorder":1,"Post Traumatic Stress Disorder":1,"Obsessive-Compulsive Disorder":1,"Depressive Disorder, Major":1,"Fibromyalgia":1,"PTSD":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Parkinson Disease Psychosis":1},"sites":[{"key":"2af82304b750e5e49e9f89c722d44575fe6978541c1a1e315e0c160897006053","facility":"Clinical Research Facility, King's College Hospital","city":"London","region":"London","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"8cd5c53de095e8abbdf7d2a81b2bc34a9a6968c44ae8f4eb45dc82ef2cf7b17c","facility":"South London and Maudsley NHS Foundation Trust","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"acb92468b8bdb8e495997bdcc5a1aab1cb194abab89bbb8f698d935f8a4f86a9","facility":"Hammersmith Medicines Research (HMR)","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"bd9ef7ba5708708e271ac4223cd8f759659fe972f273d761152a6c0134e8622e","facility":"Imperial College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"6ca657d87e4528cc481a8c1baf8515a664bf591f795d28d79266623762f21568","facility":"University College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"84d3b2e5a3a8521c2be63f3b94f0d00d44e1ecaff45bb8e80b74fbc4dd66bb3c","facility":"King's College London Institute of Psychiatry, Psychology and Neuroscience","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"a2a4ed472d0c860a706d8a130661a9baa3742799c37bd96f2f64a1cdd0866b66","facility":"King's College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"52db1aeead88bb42011a4764f5c07cbf6c76496768465bd5c4fcd8e25775a003","facility":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"6332cc00e1ef6b028ce5b2931bc428fb44a6e2eca82b5135ec346b7ceedf62ae","facility":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"190dd76ab65ad7b28570cf2992585e62e7281887f8f4acc4cc7ee1b0ebcb7c7e","facility":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"b62c29cd779fd43501f426fef3293a64089108a0e7e17ae13b4044a87d256c81","facility":"Altman Clinical and Translational Research Institute","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"bc376e1e0a696ea23f74184c3639e3209c4cf2754b05d49dcebccf226428bc05","facility":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"44dff036ba0c252b89f384cafd7b6afe7f6dbbde33d112b5813eb8a58984f3ba","facility":"Dell Medical School","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"1936d05fa8ae325b9934cffa0a0c3f08afa8e902d6fe3597cf7ffaec91b70308","facility":"Tallaght University Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"cd53ff909631c02493009d6fa3e945541560209fce31bf8b65855864408557b7","facility":"CIPPRes Clinic","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"92f7e0cc003e9611ea48c068566e59f517929115533a6bed42bf34a1e382a8a8","facility":"Imperial College Hammersmith campus","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"9b630a2a90cc4073ef88d0ddbb37bf0acd68f69db35ab18518826ea459738714","facility":"Combat Stress","city":"Leatherhead","region":"Surrey","country":"United Kingdom","lat":51.296520000000001,"lon":-0.33379999999999999},{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"b902b2ed0312cb2a3cc5ba1cbae37f314afc33004604dfd9c9cef9895f4cf659","facility":"Altman Clinical and Translational Research Institute, University of California","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"98e89c02051d49d5ecbaeeb42b54b85d2011fdba360a21f7bb381022221609db","facility":"Stanford Department of Psychiatry","city":"Stanford","region":"California","country":"United States","lat":37.424109999999999,"lon":-122.16607999999999},{"key":"4a761e46fb0059d7f502f97e7ff683ed2ef7e77e5bb9c131a2f074aa39eba6a4","facility":"Mood and Anxiety Disorders Program Emory University School of Medicine","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"f364e291f7f50ffe0211133728e04e54d4b08d8bbf7f1e2e84acca880af73791","facility":"Ray Worthy Psychiatry LLC","city":"New Orleans","region":"Louisiana","country":"United States","lat":29.954650000000001,"lon":-90.075069999999997},{"key":"9f6dd6c250948ab5fb811774c2613bdc33238e29b80a54c99b31bd3b33684089","facility":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"bc6f21f5dce4d260a52c1cf80e4684418e2cef5172a8a249513f0bd649090cc4","facility":"UT Center of Excellence on Mood Disorders, University of Texas Health Science Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"4518bb99925a2afc34b082750c6bbd85e5a2401e5aedd715ecf330439d7becd3","facility":"Canadian Rapid Treatment Centre of Excellence","city":"Mississauga","region":"Ontario","country":"Canada","lat":43.578899999999997,"lon":-79.658299999999997},{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"fcbe4ef7ab96b23d49f2236d5eef4a63ae4ba8b1ef6fda33e2d4ecdfcd59a37c","facility":"National Institute of Mental Health Czech Republic","city":"Klecany","region":"","country":"Czechia","lat":50.175989999999999,"lon":14.411479999999999},{"key":"4325121d3f92a59587a95d740aec742f926476ae029c126cfb5dca75235c060c","facility":"Enhed for Psykiatrisk Forskning, Psykiatrien i Aalborg","city":"Aalborg","region":"","country":"Denmark","lat":57.048000000000002,"lon":9.9186999999999994},{"key":"acb48d7ccc1915a74261eb4d19980566f9e91227b002d29827c3b573468fca20","facility":"Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin","city":"Berlin","region":"","country":"Germany","lat":52.524369999999998,"lon":13.41053},{"key":"4676f983baba50649c69d87e10227647f558552da403e1c02eb74db43f5954ef","facility":"Groningen University Medical Centre","city":"Groningen","region":"","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"e3f0197997fa9570956493b45ec7d746c6d8470a0084194ccfaca38d381335d5","facility":"Leiden University Medical Centre","city":"Leiden","region":"","country":"Netherlands","lat":52.158329999999999,"lon":4.4930599999999998},{"key":"8739aa2791a55723dbde929d6b1781e8da3c89797ac9f3c5cdcebc53f0be213d","facility":"Utrecht University Medical Centre","city":"Utrecht","region":"","country":"Netherlands","lat":52.090829999999997,"lon":5.1222200000000004},{"key":"0825127fed75b48491c482e72ff85f37b6d6a30ff270fa31a00aa738dfdab8b5","facility":"Unidade de Neuropsiquiatria, Centro Clinico Champalimaud","city":"Lisbon","region":"","country":"Portugal","lat":38.725090000000002,"lon":-9.1498000000000008},{"key":"8f7b027dc17f2a210264a5079ecaf11ec7851ea8acc52e06427fe3f08b1d2d69","facility":"Hospital de Dia Numancia","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"591cc23da3dbb467891a35aca8c18e00a3a00b36e679e2bc3a5c63f9cf912dff","facility":"Institute Hospital del Mar of Medical Research (IMIM)","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"4cb30a0cc2db1ef7bb013544a9f7756b74181b28b02d444b55518e6a7c5edd95","facility":"Clinical Research and Imaging Centre","city":"Bristol","region":"Avon","country":"United Kingdom","lat":51.45523,"lon":-2.5966499999999999},{"key":"ca5a318b9a8ab497d31d6e617a67f5536afaff42907d21d3392ac8c92cf5b910","facility":"Wolfson Research Centre, Campus for Ageing and Vitality","city":"Newcastle upon Tyne","region":"Tyne and Wear","country":"United Kingdom","lat":54.973280000000003,"lon":-1.6139600000000001},{"key":"2af6f49013d0328846d4ce8ee776c303f013ff687e95fd27fa857af0c681008b","facility":"St. Pancras Clinical Research","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"49c938f65ac4e8234198d3d31829a1e4505a68760ed1739762448f71dbb85a8c","facility":"Greater Manchester Mental Health Foundation Trust","city":"Manchester","region":"","country":"United Kingdom","lat":53.48095,"lon":-2.2374299999999998},{"key":"27288850d009a8b31ead8ba5cf86982457592df2fa39c3adaf10d04517cf8a5c","facility":"Sheaf House, Tallaght Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"07a8178170a30179f640b9c70731e1d415c7038aab9705b99f55e89c1cc1fb21","facility":"Mitul Mehta","city":"London","region":"Camberwell","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"enrollment":{"sum":797,"known_trials":18},"registry_checked_at_utc":"2026-10-09 01:24:43"}